shKmt2c.2 resulted in less potent knockdown than shKmt2c.1 yet produced faster tumor formation, suggesting that, as in acute myeloid leukemia (Chen et al., 2014), MLL3 can likely act as a haploinsufficient tumor suppressor in liver cancer (Figure 1—figure supplement 2E, G). Here, KMT2C is linked to liver cancer.